Remove topic bio-pharma business
article thumbnail

Potential and Challenges of the APAC Pharmaceutical Industry

Viseven

In this article, we’ll focus on a pharmaceutical market in the APAC region, go through the differences between pharma in APAC and pharma in other parts of the world, and see the current state of the APAC pharma market. This role is significant because the pharma market in APAC is increasing. from 2022 to 2027.

article thumbnail

Liminatus Pharma enters SPAC merger deal with Iris Acquisition

Pharmaceutical Technology

Liminatus Pharma has entered a definitive business combination agreement with special purpose acquisition company (SPAC) Iris Acquisition to create a business with a pro forma enterprise value of nearly $334m. These funds are expected to back the further business growth plan of Liminatus. Free Whitepaper.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Informa Connect’s IDN & Bio/Pharma Partnering Summit

Drug Channels

Informa Connect’s IDN & Bio/Pharma Partnering Summit. To address the challenges and opportunities ahead, join a distinguished group of industry pioneers at Informa Connect’s IDN & Bio/Pharma Partnering Summit —an important event for learning how to best meet the needs of these evolving networks for better patient outcomes.

article thumbnail

Informa Connect’s PAP – Patient Assistance & Access Programs

Drug Channels

This event unites pharma, foundations, health clinics and more. Do not miss this opportunity to benchmark on industry standards and stay on top of evolving trends to propel program performance. Exclusive Offer – View the agenda and register today – Be sure to use your exclusive promo code 22DCPAP10 to save 10% off * of your registration.

article thumbnail

David Pendlebury, Head of Research Analysis, Institute for Scientific Information Shares Insights from its Annual Highly Cited Researchers List

PharmaShots

Finding a group of Highly Cited Researchers, working together on the same problem at the same or a few institutions, may also indicate promising institutional affiliations for a pharmaceutical firm, if the business is focused on the same research. David Pendlebury: There are several. He worked for many years with ISI founder Eugene Garfield.

40
article thumbnail

New €300m Angelini Ventures fund combines venture creation and direct investments to pave the way for healthcare transformation

pharmaphorum

Healthcare transformation has been a widely discussed topic for years, with many arguing for a more streamlined and tech- and data-driven approach to the industry that affects all people. Looking at the future, our goals are not only to support the business, but also to diversify and build something new.”.

article thumbnail

Reuters Pharma 2022 – a day one overview – part 1

pharmaphorum

The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast. The onus, he said, was on pharma to listen now. Patient engagement – what history teaches us about pharma’s future evolution. Maximising potential, inspiring in pharma.